title: Myeloma cell contamination of peripheral blood stem-cell grafts can predict the outcome in multiple myeloma patients after high-dose chemotherapy and autologous stem-cell transplantation.
abstract: OBJECTIVE
  High-dose chemotherapy with hematopoietic stem-cell rescue is increasingly being used in the treatment of multiple myeloma. Bone marrow and also peripheral blood stem-cell (PBSC) grafts contain measurable quantities of plasma cells, the biological significance of which is unknown.
  
  
  METHODS
  Patients with multiple myeloma were mobilized with chemotherapy and filgrastim. The number of CD38++/CD138+ cells/kg in the grafts for autologous transplantation was determined by flow cytometry. Patients were stratified into two groups (threshold 4.5 x 10(5) plasma cells kg(-1)) of reinfused plasma cells in the first autologous graft.
  
  
  RESULTS
  The median statistical progression-free survival was 14 months (4-34 months) in the high-contamination group (>4.5 x 10(5) plasma cells kg(-1)) compared to 26 months (4-43 months) in the low-contamination group (<4.5 x 10(5) plasma cells kg(-1), P =0.0096). Patients with 13q deletion were more frequently found to have a high contamination of the stem-cell graft with malignant plasma cells.
  
  
  CONCLUSIONS
  Patients with graft contamination of more than 4.5 x 10(5) plasma cells kg(-1) had a high risk of early disease progression after high-dose chemotherapy. In vivo tumor cell purging prior to mobilization chemotherapy might be one strategy to improve the time to progression of high-risk patients.
authors.affiliation: Department of Internal Medicine II, Division of Hematology, Oncology, Immunology and Rheumatology, University of Tübingen, Otfried-Müller-Strasse 10, 72076 Tübingen, Germany.
authors.forename: Wichard
authors.initials: W
authors.lastname: Vogel
authors.forename: Hans-Georg
authors.initials: HG
authors.lastname: Kopp
authors.forename: Lothar
authors.initials: L
authors.lastname: Kanz
authors.forename: Hermann
authors.initials: H
authors.lastname: Einsele
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D018572:Disease-Free Survival; D005260:Female; D005434:Flow Cytometry; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D011237:Predictive Value of Tests; D014182:Transplantation, Autologous; D016896:Treatment Outcome